

Sandra PÃ©rez-Torras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3729316/publications.pdf>

Version: 2024-02-01

22
papers

606
citations

759233

12
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

1177
citing authors

#	ARTICLE	IF	CITATIONS
1	Emerging Roles of Nucleoside Transporters. <i>Frontiers in Pharmacology</i> , 2018, 9, 606.	3.5	105
2	Who Is Who in Adenosine Transport. <i>Frontiers in Pharmacology</i> , 2018, 9, 627.	3.5	85
3	Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. <i>Frontiers in Pharmacology</i> , 2015, 6, 13.	3.5	84
4	Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. <i>Journal of Pharmacological Sciences</i> , 2015, 127, 319-325.	2.5	45
5	Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. <i>Biochemical Pharmacology</i> , 2008, 76, 322-329.	4.4	40
6	Intestinal Nucleoside Transporters: Function, Expression, and Regulation. , 2018, 8, 1003-1017.		35
7	Connexin-26 Is a Key Factor Mediating Gemcitabine Bystander Effect. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 505-517.	4.1	33
8	Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs. <i>BMC Cancer</i> , 2012, 12, 434.	2.6	28
9	Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner. <i>Cell Death and Disease</i> , 2013, 4, e648-e648.	6.3	26
10	Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 511-521.	4.4	23
11	Transportome Profiling Identifies Profound Alterations in Crohn's Disease Partially Restored by Commensal Bacteria. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 850-859.	1.3	21
12	Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors. <i>BMC Cancer</i> , 2015, 15, 223.	2.6	16
13	New role of the human equilibrative nucleoside transporter 1 (hENT1) in Epithelial to mesenchymal transition in renal tubular cells. <i>Journal of Cellular Physiology</i> , 2012, 227, 1521-1528.	4.1	15
14	Role of the Transporter Regulator Protein (RS1) in the Modulation of Concentrative Nucleoside Transporters (CNTs) in Epithelia. <i>Molecular Pharmacology</i> , 2012, 82, 59-67.	2.3	12
15	Deficiency of perforin and hCNT1, a novel inborn error of pyrimidine metabolism, associated with a rapidly developing lethal phenotype due to multi-organ failure. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1182-1191.	3.8	8
16	Dexamethasone-Loaded Lipomers: Development, Characterization, and Skin Biodistribution Studies. <i>Pharmaceutics</i> , 2021, 13, 533.	4.5	7
17	The Physicochemical, Biopharmaceutical, and In Vitro Efficacy Properties of Freeze-Dried Dexamethasone-Loaded Lipomers. <i>Pharmaceutics</i> , 2021, 13, 1322.	4.5	7
18	Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. <i>Oncotarget</i> , 2017, 8, 90185-90196.	1.8	6

#	ARTICLE	IF	CITATIONS
19	Pharmacogenomic analysis of the responsiveness of gastrointestinal tumor cell lines to drug therapy: A transcriptome approach. <i>Pharmacological Research</i> , 2016, 113, 364-375.	7.1	4
20	FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia. <i>Pharmacological Research</i> , 2020, 151, 104556.	7.1	3
21	OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 7505-7518.	5.4	2
22	An Escape-Room about Krebs cycle prepared for Chemical Students. <i>International Journal on Engineering, Science and Technology</i> , 2022, 3, 155-164.	0.4	1